Switzerland's Role in Global Biotechnology Innovation

This document is a report detailing Switzerland's prominent position in the global biotechnology sector. It outlines the country's achievements in translating scientific research into commercially viable biotech businesses, highlighted by its top ranking in the WIPO Global Innovation Index for 13 consecutive years. The report notes that since 2020, Swiss biotech firms have raised approximately CHF10 billion in financing, with significant international collaboration evident in the licensing and partnership deals made by these companies. The R&D pipeline of Swiss biopharmaceuticals is substantial, with around 1,200 assets under development, focusing on therapeutic areas such as oncology, neurology, and metabolic diseases. The document emphasizes the importance of international partnerships and the role of major players like Novartis and Roche in driving innovation and commercialization in the sector. Furthermore, it discusses Switzerland's manufacturing capabilities, which serve a global market, reinforcing its status as a key player in the biotechnology landscape.